Duvax: a dual vaccine aimed at Alzheimer's disease prevention for adults
Official title: Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
Funded at Nuravax, INC. · NIH-11530756 · Data updated 2026-11-12
A new study is testing a vaccine called Duvax designed to be safe and tolerated in healthy adults to help prevent or delay Alzheimer's disease by targeting two key brain proteins, amyloid beta and tau.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nuravax, INC. NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | April 1, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,257,282 |
| NIH project number | 4R44AG091903-02 |
| Project ID | NIH-11530756 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 21 and older, including those without dementia, who are healthy or at risk for AD may be eligible to participate.
✕Less likely to help
Individuals with established Alzheimer's disease or significant cognitive impairment are unlikely to benefit from this preventive vaccine study.
What this research studies
This project explores a preventive vaccine approach for Alzheimer's disease by using an adjuvanted dual vaccine platform to address amyloid beta and tau pathology. The study will enroll healthy adults to assess safety, tolerability, and immune response to the Duvax vaccine. Researchers will monitor immune activity and any adverse effects over time to determine suitability for future trials in at‑risk populations or early disease stages. If successful, this work could lay the groundwork for a translational path toward delaying or reducing the onset of symptoms in individuals with elevated risk for AD.
Why it matters
Potential benefit: If successful, the vaccine could contribute to delaying the onset or progression of Alzheimer's disease in at‑risk individuals by reducing pathological processes in the brain.
How similar studies have gone: Previous AD vaccine efforts have shown mixed safety profiles; this dual-antiamyloid/tau approach represents a novel, early-stage testing in humans.
Where this research is happening
-
Nuravax, INC.
Irvine, United States Active
Researchers
- Principal investigator: Cribbs, David Hastings — Nuravax, INC.
- Study coordinator: Cribbs, David Hastings
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.